Podcasts about psychedelic science

In this episode Rotem Petranker, PhD joins to discuss the current state of research on microdosing psilocybin. Dr. Petranker is the co-founder of the Psychedelic Studies Research Program at the University of Toronto and the Canadian Centre for Psychedelic Science. He recently ran the world's largest randomized controlled trial on the effectiveness of microdosing psilocybin on Major Depressive Disorder. In this conversation, Dr. Petranker shares insights from running the world's largest randomized controlled trial on psilocybin microdosing for major depressive disorder. He explains the origins of microdosing research, from early anecdotes and surveys to his team's carefully designed clinical study comparing psilocybin to placebo across different environments. While participants in both groups reported significant improvements, the findings point to the powerful role of expectancy and placebo effects, alongside nuanced signals of cognitive shifts on measures like dysfunctional attitudes. Dr. Petranker emphasizes the importance of rigorous methodology, open science, and transparency in psychedelic research, while also acknowledging the stories of participants whose lives were positively impacted by study participation itself.   In this episode, you'll hear: What early microdosing research suggested, and its limitations in anecdotal and survey-based designs Why psilocybin was chosen over LSD for the study design  What motivates people to try microdosing a psychedelic Key results from Dr. Petranker's study, including reports of both positive and adverse events How placebo effects—and simply being part of a trial—can powerfully shape outcomes Reflections on how psychedelics may work by increasing connectedness   Quotes: “There's no real rigorous definition [of microdosing]. People say, ‘oh, I'm just going to microdose some mushrooms,' and then they often take a random amount. I think what people mean is ‘I'm going to take an amount that will not knock me out, won't cause serious hallucinations,' but they still use an amount that they often feel. Now, this is in contrast to what people in the [academic] literature define it as, which is more like a sub-perceptual dose, a sub-hallucinogenic dose.” [2:17] “If you microdose and go to work, just to sit under the flickering lights for eight hours in your cubicle versus, say, if you're going to microdose and then go on a walk, or do art, or do as you wish because it's the weekend, you're going to have very different impacts on your anxiety.” [15:26] “[In our study] there were three other self-report measures of depression. There is only a significant difference on one of them, where people who were microdosing were doing better. And that was on the dysfunctional attitude scale, which measures more cognitive assumptions about life.” [26:2] “people who microdose—regardless of why they microdose—they more or less all said that they got to what they wanted through an increased sense of meaning.” [35:05]   Links: Psychedelic Studies Research Program at the University of Toronto Canadian Centre for Psychedelic Science website Canadian Centre for Psychedelic Science on X Canadian Centre for Psychedelic Science on Instagram Previous episode: Microdosing and the Placebo Effect with Balazs Szigeti, PhD Previous episode: James Fadiman answers your Microdosing Questions! Psychedelic Medicine Association Porangui  

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

During the early weeks of the pandemic, Tim Hayward spent 14 days in a coma. He remembers this time vividly – his days and nights filled with strange, incandescent visions and hallucinations. That experience is something he would never choose to revisit but, around the world, large numbers of people are deliberately seeking out powerfully altered states.In this ten-part series, Tim sets out to better understand a group of substances that induce altered states: psychedelics.There's been a surge of interest in their therapeutic potential for various mental health conditions - as well as a range of other clinical possibilities. As research around the world ramps up after years of taboo and prohibition he tries to get to grips with - or at least get a clearer sense of - how science, culture, politics and business might all interact in this changing psychedelic landscape, and what it all might mean.He also explores what might be happening in the brain during a trip and whether, by studying psychedelics, we might uncover more about consciousness, imagination and even the mysteries of reality itself.In this episode, we hear from members of the psychedelic community who fear the consequences of plants and fungi that are sacred to some indigenous communities being exploited for commercial gain. This would not be the first time, they say - just look at what happened with tobacco.Contributors: Osiris García Cerqueda, historian and sociologist, Program Coordinator, Indigenous Reciprocity Initiative (IRI) Ariel Clark, lawyer and founding member of the Psychedelic Bar Association Mike Jay, author and cultural historianPresenter: Tim Hayward Series Producer: Richard Ward Executive Producer: Rosamund Jones Editor: Kirsten Lass Written by Tim Hayward and Richard Ward Sound Design and Mixing: Richard Ward Researcher: Grace Revill Production Executive: Lisa Lipman Commissioning Editor: Daniel Clarke A Loftus Media production for BBC Radio 4Audio footage from Psychedelic Science 2023 and 2025 used with permission from the Multidisciplinary Association for Psychedelic Studies (MAPS).

Medicine has come a long way in the past 50 years, but here's what's fascinating: many of the breakthrough treatments we use today for pain, addiction, and mental health started with a handful of doctors who were willing to go against the grain.In this conversation, Sam sits down with Dr. Howard Kornfeld, a triple board-certified physician whose career reads like a roadmap of medical innovation. We're talking five decades of pushing boundaries - from emergency medicine to nuclear war prevention to being at the ground floor of psychedelic research.Dr. Kornfeld doesn't just share stories (though he has plenty). He walks us through his transformative experiences at Esalen Institute, his pioneering work with buprenorphine treatment, and his connections to the key figures who literally shaped modern psychedelic medicine as we know it.What makes this conversation essential listening? Dr. Kornfeld's journey shows exactly how questioning established medical practices - while still maintaining rigorous, evidence-based standards - can lead to treatments that actually change lives. His story proves that individual physicians can drive real systemic change, but it requires persistence, innovation, and the willingness to work outside conventional healthcare systems.If you've ever wondered how breakthrough treatments actually make it from "experimental" to mainstream, or if you're curious about what it really takes to challenge medical orthodoxy, this conversation will give you the historical context you need.What You'll Learn in This Episode・How questioning medical orthodoxy led to breakthrough treatments and career-defining insights・The evolution of pain medicine from the 1920s through today and lessons for modern practice・Dr. Kornfeld's journey from emergency medicine through nuclear activism to integrative practice・Historical context for psychedelic medicine's current renaissance and key pioneering figuresEpisode 39 show notes:00:00 Teaser - Physicians as Shamans of Our Culture00:34 Welcome Back To the Podcast 03:04 Challenging Medical Orthodoxy: The Mastectomy Story 07:04 Triple Board Certification Journey 09:41 Cook County Hospital vs Prestigious Academics 12:55 Esalen Institute: A Medical Education Like No Other 17:37 Three Mile Island and Nuclear War Prevention 31:08 Meeting Sasha Shulgin and Early MDMA Research 35:32 Entering Addiction Medicine36:43 The Esalen Psychedelic Research Conference 49:05 From Nuclear Activism to Addiction Medicine 53:037 Buprenorphine: Years Ahead of Everyone Else 1:00:14 The Pendulum Swings of Pain Medicine 1:14:15 Recovery Without Walls Clinic Model 1:17:37 Ketamine's Paradoxical Nature in Addiction 1:20:38 Treating Ketamine Use Disorder 1:22:20 Starting Your Own Practice: Practical Advice 1:28:21 Advice from Your 100-Year-Old Self 1:31:52 Contact Information and ClosingThanks for listeningConnect with Dr. Howard Kornfeld at:Recovery Without Walls

From the Rave Scene to Psychedelic Therapy In this episode, Kyle Buller speaks with Matt Xavier, DJ, therapist, and author. The conversation took place live at Psychedelic Science. Matt recalls his early years in the rave culture of 1990s New York. He ran record labels, hosted psychedelic trance events, and lived through the intensity of that scene. Why Music Is Medicine Matt believes music should be treated as medicine. He explains how playlists can align with the stages of a psychedelic journey—onset, climb, peak, and descent. He encourages people to listen with intention and to categorize tracks by emotion, energy, and therapeutic impact. Psychedelic Soundtracking Instead of relying only on fixed playlists, Matt performs live mixing during sessions. This method keeps him fully engaged and responsive. He calls the approach “psychedelic soundtracking.” In his view, the guide becomes a tuning fork, adjusting the soundscape to match the client's process. Key Themes in the Conversation The evolution from rave DJ to therapist and author How music amplifies psychedelics, and why it matters Matching music with each stage of a journey Differences between psilocybin, MDMA, and ketamine work The value of silence, long-form tracks, and harmonic mixing Why buying music supports artists and protects creativity from AI Practical tips for building playlists and rediscovering a love of listening Supporting Artists and Building Community Matt highlights the artists who inspire his work, from ambient pioneers to contemporary sound designers. He urges practitioners to support independent musicians by purchasing their music. In his words, keeping human creativity alive is essential for meaningful psychedelic work. Writing, Mixing, and the Future Matt also discusses his new book and the curated four-hour DJ protocol mix he designed for therapy sessions. He explains how this project grew into a collaborative effort and why writing became a spiritual journey for him. Looking ahead, he hopes to create a training program for others interested in weaving music into psychedelic practice.

Dr. Roger McFillin sits down with Charity Mills, CEO of Colorado Teletherapy Services and Grow Your Own Thoughts, to discuss the science, stigma, and life-changing stories behind psilocybin microdosing. From PTSD to treatment-resistant depression, they discuss why traditional therapies and pharmaceuticals often fall short, and how microdosing may offer a safer, more sustainable path to healing for those struggling to recover. Charity shares her personal journey, clinical experience, and the protocols she's developed for hundreds of clients. Dr. McFillin also reveals his own surprising experience using psilocybin and his discoveries.  Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

In this episode of The Psychedelic Podcast, host Paul F. Austin welcomes cultural historian and acclaimed author Mike Jay. Find full show notes and links here: https://thethirdwave.co/podcast/episode-316/?ref=278 Together they explore the untold history of nitrous oxide, psychedelic experimentation in the Romantic era, and the deeper cultural and philosophical roots of psychedelic science. Mike shares insights from his latest book, Free Radicals, highlighting how figures like Humphry Davy and William James helped shape psychedelic thought long before the 1960s. The conversation weaves through ancient San Pedro rituals, colonial attempts to suppress peyote use, and the divergent paths of modern psychedelic medicine. From poetic self-experimentation to medicalized models, Mike unpacks the historical tensions between grassroots healing and institutional control—and what this means for the future of psychedelic culture. Mike Jay is a British author and cultural historian who has written widely on the history of drugs, consciousness, and medical science. His books include Mescaline: A Global History of the First Psychedelic, Psychonauts: Drugs and the Making of the Modern Mind, and Free Radicals: How a Group of Romantic Experimenters Gave Birth to Psychedelic Science. Mike contributes regularly to The London Review of Books, The New York Review of Books, and The Wall Street Journal. Highlights: How early scientists used nitrous oxide for inner exploration Romantic poets as the original psychedelic self-experimenters Parallels between Humphry Davy and Alexander Shulgin What William James learned from nitrous, not mescaline Colonial suppression of peyote and indigenous resilience The enduring symbolism of San Pedro in Andean ritual How the counterculture reinterpreted Native practices Why modern psychedelic medicine may be repeating history The role of finance in shaping current therapy models Looking ahead: divergent futures of psychedelic healing Episode links:  Mike's website Mike's new book, Free Radicals Mescaline: A Global History of the First Psychedelic Psychonauts: Drugs and the Making of the Modern Mind Manvir Singh's article in The Guardian “The Peyote Dance” by Antonin Artaud Episode sponsors:  Psychedelic Coacing Institute's Intensive for Psychedelic Professionals in Costa Rica - a transformative retreat for personal and professional growth. Golden Rule Mushrooms - Get a lifetime discount of 10% with code THIRDWAVE at checkout

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

Mike Jay has written extensively on scientific and medical history and contributes regularly to the London Review of Books and the Wall Street Journal. His previous books on the history of drugs include High Society, Mescaline and Psychonauts. On this episode of Little Atoms he talks to Neil Denny about his latest book Free Radicals: How a Group of Romantic Experimenters Gave Birth to Psychedelic Science. Hosted on Acast. See acast.com/privacy for more information.

This is the third special episode I recorded in collaboration with Joe Moore from Psychedelics Today at the largest conference in the field "Psychedelic Science 2025" in Denver last week. It very early in the morning, at 8am, and it was fabulous. Our guests in this episode are the hilarious comedian Dennis Walker, the energetic Co-founder (with Myriam Barthes) and CEO of Journey Clinical Jonathan Sabbagh, Philip Drechsel, my Co-Founder of The New Health Institute, and Tom Feegel, Co-Founder of the ibogaine clinic Beond (with Talia Eisenberg) Joe and I talk about the language of healing and how we communicate this to others, when we need to change all together. As Philip shared his healing story with ibogaine, it became clear what a healing opportunity we could experience here. FOLLOW ON IG:The@mycopreneurofficial @jonathansabbagh @beyond.us @thenewhealthinstitute @thenewhealthclub @psychedelicstoday Hosted on Acast. See acast.com/privacy for more information.

In this episode of Cultish, we sit down with researcher and author Carl Teichrib to explore the spiritual revolution unfolding in the heart of the psychedelic renaissance. From the stages of Psychedelic Science 2025 to the language of “entheogens,” we unpack how science and mysticism are merging to create a new global belief system—one that aims to replace traditional religion with a chemically-induced inner divinity. Are psychedelics truly neutral tools for healing, or are they sacraments of a rising, gnostic worldview? What are the global implications of this spiritual transformation, and why should Christians pay attention? Tune in as we expose the psychedelic agenda of the world—and what it means for the future of faith and truth.Partner With Us: HERE Buy Carl's book Game of Gods HERECarl's Substack HERE

In this expansive episode of Psychedelics Today, Joe Moore sits down with author and cultural theorist Daniel Pinchbeck to explore the evolving—and increasingly contested—role of psychedelics in society. From the hopeful spirit of transformation that animated earlier psychedelic movements to the sobering reality of biotech, branding, and political entanglement, Daniel offers a candid diagnosis of where we are—and where we might be headed. Reflecting on Psychedelic Science 2025, Daniel discusses the event's stark shift toward commercialization and industry influence. He contrasts this with his earlier work on Evolver, a movement that sought to integrate psychedelics with permaculture, alternative economics, and cultural awakening. Together, Joe and Daniel examine how the field's idealistic origins have been increasingly subjected to capitalist co-option. They also dive into deeper philosophical terrain—discussing monistic idealism, Rudolf Steiner, and the suppression of mystical and paranormal dimensions in the push to medicalize and sanitize psychedelics for mainstream acceptance. Daniel warns of the dangers of ignoring the shadow, including psychic fragmentation and what he calls "entity attachment" from ungrounded use. The conversation ranges from tech billionaires on ketamine to the geopolitical threat of authoritarianism, the weaponization of AI, and the quiet complicity of many in the psychedelic space who avoid political engagement. Daniel shares his current projects, including his Substack newsletter and a new seminar, Breaking the AI Barrier. This is a timely, unflinching exploration of psychedelics as both medicine and mirror—revealing the best and worst of our collective intentions. Can we reclaim the visionary potential of these tools from the grip of capital and control?

This is a special episode I recorded in collaboration with Joe Moore from Psychedelics Today at the largest conference in the field "Psychedelic Science 2025" in Denver last week. It very early in the morning, at 8am, and it was fabulous. Our guests: Daniel Goldberg Co-Founder and Partner at Palo Santo & Bridge Investments & Zac Kamenetz, Founder of Shefa: Jewish Psychedelic Support, Joe and me were talking about the interactions of psychedelic community, the new role of Venture Capital in 2025 and what psychedelic systems are built in the current climate to support individuals and the bigger picture. Check out this episode, it's fun and very insightful.Check out:https://www.shefaflow.org/https://palosanto.vc/ Hosted on Acast. See acast.com/privacy for more information.

I mean, you've got'a laugh, aintcha! Nitrous Oxide made “a picaresque journey from laboratory to lecture hall, variety palace to dentist's chair.” A substance that does not exist in nature, it fairly blew the minds of the radical scientific community in the late 18th Century when it was isolated and synthesised. Some of them couldn't decide whether it was more remarkable medicinally or recreationally. What they did know was that it was a wonderful product of a modern scientific sensibility. It is a story that takes in Joseph Priestley, Erasmus Darwin, Samuel Taylor Coleridge, Robert Southey, Humphrey Davy, Peter Mark Roget (yes, that Roget), James Watt, and at its centre, … Continue reading →

In this wide-ranging conversation, journalist Mattha Busby joins Joe Moore to reflect on the shifting tone of the psychedelic movement in the wake of Psychedelic Science 2025. Based in Vancouver, Mattha has written for The Guardian, VICE, Esquire, TIME, and Wired, bringing a uniquely embedded yet critical lens to the space. They discuss the post-conference mood and the sense that the industry is sobering up—less hype, more introspection. Mattha reflects on the growing division between underground practitioners, activists, and biotech startups, and the importance of vision, ethics, and scrutiny in the midst of this cultural moment. Other topics include: Ketamine overuse and dependence, especially in social and parenting contexts The future of psychedelic nightlife, harm reduction, and mocktail bars Gender and sexual fluidity as uncovered through psychedelics Questions of IP, underground wisdom, and psychedelic ownership Psychedelics as tools for peacebuilding, especially in conflict zones The shadow side of spiritual experiences and how to spot bad actors The value of pleasure, intimacy, and human connection in the psychedelic journey Joe and Mattha also reflect on the resurgence of psychedelic use in Texas, the legacy of the Stark Club, and how Christian libertarianism and military trauma might influence unexpected policy changes. This conversation is bold, honest, funny, and thoughtful—exactly the kind of cultural critique the movement needs right now. Find Mattha on Instagram at @matthamundo and on LinkedIn at Mattha Busby. His new pocketbook on drug policy is available now.

In Episode 127 of the MAX Afterburner podcast, Whiz opens with a powerful celebration of progress in the healing space. He highlights Robert F. Kennedy Jr.'s recent statement to Congress, where the HHS secretary boldly called for psychedelic therapies to be made available to veterans within the next 12 months. Whiz also spotlights a landmark five-year study from The Ohio State University showing that a single heroic dose of psilocybin helped 67% of participants recover from depression—with no relapse.Whiz then offers a transparent debrief on why the No Fallen Heroes Foundation didn't attend the Psychedelic Science conference in force - 'a self licking ice cream cone & echo chamber'. He expresses concern over the commercialization of the healing movement and directly calls out several for-profit ibogaine clinics in Mexico for price gouging vulnerable veterans and families in crisis. “Healing shouldn't come with a luxury price tag,” he says.The episode takes a deeper turn as Whiz addresses recent criticism surrounding Operation Midnight Hammer and the perceived contradiction of “celebrating war” while preaching healing. He responds with clarity and conviction, saying he is against all war—calling it the ultimate failure of human consciousness. But, he argues, if war must happen, it should be so brutal and unforgiving that it deters future conflict. He also shares a powerful reflection on the archetype of “the man who wanted to be left alone,” framing it as a cautionary tale for a world that pushes healed warriors too far.Finally, Whiz reflects on the last four years of his own journey—filled with setbacks, breakthroughs, and relentless work. He declares this moment “the end of the beginning”—and affirms that the real mission, the deeper healing and transformation, begins now.

Acaba de acontecer em Denver, no Colorado, a maior conferência de ciência psicodélica do mundo, que recebeu 8 mil visitantes e contou com mais de 500 palestrantes que apresentaram as últimas novidades na pesquisa científica com psicodélicos. Neste episódio, trocamos uma ideia com a Fernanda Palhano, engenheira e neurocientista do Instituto do Cérebro da UFRN (Universidade Federal do Rio Grande do Norte), que participou do evento junto com um grupo de outros renomados cientistas que estudam a aplicação de psicodélicos para a saúde mental.A comitiva brasileira da qual Fernanda faz parte foi o destaque absoluto da Psychedelic Science 2025, apresentando achados recentes com ayahuasca, DMT e cetamina, provando mais uma vez que o Brasil está entre os três países do mundo mais avançados nessa área.Aperta o play e vem comigo conhecer os insights sobre a maior conferência psicodélica do mundo!***Encontre a Fernandano Linkedinhttps://www.linkedin.com/in/fernanda-palhano-fontes-453915207/no Instahttps://www.instagram.com/fernanda_palhano/no emailfernandapalhano@neuro.ufrn.brEncontre o Camphttps://www.camp-sci.com/pt***Fernanda indicaLivros do Marcelo LeitePsiconautasA ciência encantada de Jurema***MARCAS APOIADORAS DA 4ª TEMPORADAUnyleya: https://unyleya.edu.br/anitakreppUSA Hemp: https://www.usahempbrasil.com/Flora Urbana: https://floraurbana420.com.br/Blis: https://appblis.com.br/aLeda: https://www.instagram.com/aledaoficial/***Essas são marcas que reconhecem o valor da comunicação responsável e do jornalismo de qualidade no processo de desestigmatização da planta, promovendo informação para a normalização do que um dia foi tabu.***Para seguir por dentro dos avanços da cannabis e dos psicodélicosAssine a news: https://cannabishoje.substack.com/Siga no Insta: https://www.instagram.com/cannabishoje/Se inscreva no Youtube: https://www.youtube.com/@cannabishojeAcesse: https://cannabishoje.com.br/

Join host Gregg Masters on this special episode with Jim Tate as they dive into the upcoming MAPS Psychedelic Science 2025 conference—from June 16–20th in Denver, CO. They explore the evolving science and policy landscape around psychedelic-assisted therapies for trauma and mental health, with a special focus on veterans and first responders. Tune in to hear insights on MDMA and psilocybin trials, federal and VA implementation, peer support models, and the role of community and cultural healing. With voices from researchers, practitioners, and lived-experience advocates, this episode previews what promises to be a transformative moment in public health. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/This Band willl Blow your Mind! Codex Serafini: https://codexserafini.bandcamp.com/album/the-imprecation-of-animaLeaving Psychedelic Science, thoughts, highlights & the future of Psychedelics…Sabbahttp://linkedin.com/in/sabbanazhandJackhttps://linktr.ee/JackGorsline?utm_source=linktree_profile_share<sid=7e7b5bf8-8996-4502-a1d0-57ade0c01233 Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USCheck out our YouTube:https://youtube.com/playlist?list=PLPzfOaFtA1hF8UhnuvOQnTgKcIYPI9Ni9&si=Jgg9ATGwzhzdmjkgGrow your own:https://modernmushroomcultivation.com/This Band Will Blow Your Mind: Codex Serafinihttps://codexserafini.bandcamp.com/album/the-imprecation-of-anima

This is a special episode I recorded in collaboration with Joe Moore from Psychedelics Today at the largest conference in the field "Psychedelic Science 2025" in Denver last week. It very early in the morning, at 8am, and it was fabulous. Our guests: Tommaso Barba, Neuroscientist from Imperial College London and Dee Dee Goldpaugh, therapist, author and clinical consultant, me and Joe were talking about Sex, Intimacy and Psychedelics! Check out this episode, it's fun and very insightful.IG: @Tommaso.barba @deedeegoldpaugh @psychedelicstoday Hosted on Acast. See acast.com/privacy for more information.

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/This Band willl Blow your Mind! Codex Serafini: https://codexserafini.bandcamp.com/album/the-imprecation-of-animaJenny Chen RobertsonIn an empire of numbness, where sedation is sold as salvation,One woman dares to weaponize wisdom and baptize bureaucracy in the psilocybin sacrament.”Jenny is not a facilitator.She is a forger of frameworks,A cartographer of care,Turning risk-reduction into revolution.She walks the fault line between clinical ethics and ecstatic experience—MBA-trained, yes—But with soul credentials inked in sweat, in silence,In sacred listening.She's briefed lawmakers with the calm of a nun and the clarity of a sniper.She's testified with tremors in her voice and steel in her spine.Her resume reads like a paradox:Real estate magnate turned mycelial matriarch.Spreadsheet whisperer turned soul doula.Jenny co-founded the Safer Psychedelics Association of New EnglandNot to play nice with power—But to redefine it.She speaks for the trip-gone-sideways,For the mothers who don't trust “the system,”For the cops confused by consciousness,For the firemen called to burning minds.This isn't harm reduction—it's harm revolution.This isn't education—it's uncolonized knowing.She doesn't just talk set and setting—She re-sets the setting of the entire conversation.So lean in close, fam—Because when Jenny speaks,The old paradigm doesn't just shudder—It begs for a blindfold.And the future?It's already listening.SPAN: Safer Psychedelics Association of New EnglandJenny Chen Robertson Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USCheck out our YouTube:https://youtube.com/playlist?list=PLPzfOaFtA1hF8UhnuvOQnTgKcIYPI9Ni9&si=Jgg9ATGwzhzdmjkgGrow your own:https://modernmushroomcultivation.com/This Band Will Blow Your Mind: Codex Serafinihttps://codexserafini.bandcamp.com/album/the-imprecation-of-anima

Hoje eu trago para vocês um papo emocionante com Marilene Esperança, primeira mulher negra a comandar uma associação de pacientes de cannabis no Brasil, a Abrario, que recentemente obteve na Justiça do Rio de Janeiro o direito de cultivar, manipular, transportar e distribuir maconha para fins terapêuticos aos associados. A decisão destaca que nem Anvisa e nem a União podem restringir o cultivo medicinal, uma vez que não há legislação específica que o proíba. Marilene detalha como esse processo inédito se desenrolou e como agora inspira outras associações, inclusive as mais antigas que a Abrario, a buscar o mesmo direito.Vem comigo pra entender a conquista inédita da Abrario e que a Anvisa não apita em associação de pacientes.***Encontre a Marilenehttps://www.instagram.com/marilene_esperanca/Encontre a Abrariohttps://www.instagram.com/abrariooficial/***Marilene indicaIlegal, a vida não espera (documentário no Youtube)***Cobertura do Psychedelic Science 2025 para o Poder360https://www.poder360.com.br/tag/psychedelic-science-conference/***MARCAS APOIADORAS DA 4ª TEMPORADAUnyleya: https://unyleya.edu.br/anitakreppUSA Hemp: https://www.usahempbrasil.com/Flora Urbana: https://floraurbana420.com.br/Blis: https://appblis.com.br/aLeda: https://www.instagram.com/aledaoficial/***Essas são marcas que reconhecem o valor da comunicação responsável e do jornalismo de qualidade no processo de desestigmatização da planta, promovendo informação para a normalização do que um dia foi tabu.***Para seguir por dentro dos avanços da cannabis e dos psicodélicosAssine a news: https://cannabishoje.substack.com/Siga no Insta: https://www.instagram.com/cannabishoje/Se inscreva no Youtube: https://www.youtube.com/@cannabishojeAcesse: https://cannabishoje.com.br/

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/This Band willl Blow your Mind! Codex Serafini: https://codexserafini.bandcamp.com/album/the-imprecation-of-animaLewis Goldberg Ladies and gentlemen, seekers of signal in the static,allow me to introduce a voice forged in the alchemical fireof policy, purpose, and paradox.Lewis Goldberg is not just a publicist.He's a linguistic locksmith,a master of messaging who doesn't just shape narratives —he whispers to the current underneath them.With the war drums of old Washington echoing in his blood,he cut his teeth in the mythos of power:Clinton's campaign trail, Torricelli's tightropes,the ever-calculating eye of a First Lady named Hillary.But then —like any good archetypal wanderer —he turned toward the plant path.Toward cannabis, toward psychedelics,toward the revolution happening beneath our feet.He didn't just pivot — he prophesied.In 2015, he helped launch KCSA's cannabis division,giving shape and story to an industryrising like smoke through the cracks of a crumbling paradigm.He co-hosts The Green Rush,a podcast that is part intelligence briefing,part esoteric transmission for the business-minded psychonaut.And while some men worship quarterly reports,Lewis builds cathedrals in the stock ticker —rooting for the underdogs,channeling the sacred absurdity of Mets games,Jets heartbreaks,and the eternal optimism of Rutgers fanswho believe — against all odds —that truth, like victory, can be summoned with enough heart.So today, as we stand on the thresholdof Psychedelic Science 2025,we welcome not just a strategist —but a conjurer of attention.A myth-maker of market forces.A Blakean bard in a tailored blazerwho reminds us that even in the most corporate corners of culture…something sacred still wants to break through.Give it up for Lewis Goldberg. Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USCheck out our YouTube:https://youtube.com/playlist?list=PLPzfOaFtA1hF8UhnuvOQnTgKcIYPI9Ni9&si=Jgg9ATGwzhzdmjkgGrow your own:https://modernmushroomcultivation.com/This Band Will Blow Your Mind: Codex Serafinihttps://codexserafini.bandcamp.com/album/the-imprecation-of-anima

A major psychedelics conference wraps up in Denver today. Its mission is to get more people, especially policy makers, comfortable with what has been underground. We speak with the founder of MAPS, the Multidisciplinary Association of Psychedelic Science, about the science and what's left to learn as Colorado licenses psilocybin healing centers. Plus a company in clinical trials, and an awareness campaign about the potential risks. Then, nurse Tara Rynders used to hold in all the trauma of the job. But through music and movement, she's managed to change that for herself and for other practitioners. Now she has a one-woman show, "A Nurse is Calling."

n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world's leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale.  Trevor shares his early work supporting marginalized populations in Vancouver's Downtown Eastside, which led to the founding of Liberty Root, one of Canada's first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021. They discuss: The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk. Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California. Ambio's groundbreaking neuroregenerative program for Parkinson's, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker. How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford's 2024 study on Special Forces veterans. Why ibogaine isn't just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care. The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains. Their cautionary perspective on Texas' $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing. They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn't just part of the movement; it's the blueprint for how ibogaine could be delivered worldwide. Links: Ambio Website: https://ambio.life/ Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025) Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024) Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion (Frontiers in Pain Research, Aug 2023) Novel treatment of opioid use disorder using ibogaine and iboga in two adults (Journal of Psychedelic Studies, Jan 2020) Clinical Guidelines for Ibogaine-Assisted Detoxification Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions Bios:  Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world's leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field's foundational safety guidelines and has published widely on ibogaine's therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine's potential for trauma, TBI, pain, MS, and Parkinson's. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity. Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine's applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.

Psychedelic therapy is on the verge of reshaping mental health, trauma healing, and human consciousness. This episode reveals what's really happening behind the scenes at the FDA, inside pharmaceutical companies, and within the global movement to legalize MDMA-assisted therapy. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Rick Doblin, PhD, the legendary founder of MAPS and one of the most influential figures in psychedelic science. With nearly 40 years leading clinical research on MDMA, psilocybin, and trauma healing, Rick brings unmatched insight into how these compounds are transforming functional medicine, emotional resilience, and neuroplasticity. They break down the regulatory battle over MDMA therapy, the clash between pharmaceutical profit and public benefit, and the urgent need to combine pharmacology with therapy for real results. You'll also learn how psychedelics impact neurohacking, epigenetics, and the default mode network—and why the next frontier of self-transformation may be couples therapy with MDMA. This episode offers critical knowledge for anyone serious about biohacking, trauma release, mental performance, and accessing deeper states of healing. This podcast channel dives into the intersections of psychedelics with fasting, ketosis, cold therapy, and self-quantification—and how altered states can unlock more energy, better relationships, and lasting change. You'll Learn: • Why separating therapy from psychedelics is the most dangerous path forward • How MAPS evolved into a public benefit pharma company—and what went wrong • The real story behind the FDA's rejection of MDMA therapy in 2024 • How MDMA affects neuroplasticity, mitochondria, and trauma recovery • Why group therapy and couples therapy are the future of psychedelic healing • The dangers of overusing ketamine—and how it's being exploited by profit-driven clinics • What the Psychedelic Science 2025 conference will reveal about the future of medicine, spirituality, and consciousness hacking • How psychedelics could reverse epigenetic trauma passed down through generations • The role of default mode network suppression in spiritual experiences and trauma resolution • Why the war on drugs was never about safety—and what a post-drug-war world might look like Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade is the top podcast for people who want to take control of their biology, extend their longevity, and optimize every system in the body and mind. Each episode features cutting-edge insights in health, performance, neuroscience, supplements, nutrition, neurohacking, emotional intelligence, and conscious living. Episodes are released every Tuesday and Thursday, where Dave asks the questions no one else dares, and brings you real tools to become more resilient, aware, and high performing. SPONSORS: - Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off- ARMRA | Go to https://tryarmra.com/ and use the code DAVE to get 15% off your first order Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • Psychedelic Science Conference 2025 Website – https://www.psychedelicscience.org/ • Rick's Website: https://maps.org/ • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 Trailer • 02:00 Intro • 03:43 Rise of Psychedelic Pharma • 05:00 Therapy vs. Profit • 06:44 Neurofeedback + Psychedelics • 08:28 Origins of Drug Laws • 14:06 MDMA Safety + Usage • 16:32 Psychedelics in Therapy + Meditation • 25:18 Psychedelic Hierarchy for New Users • 26:51 Psychedelic Churches + Culture • 28:58 Ayahuasca: Spiritual Insights • 30:24 MDMA and Federal Policy • 31:09 Inside the FDA Decision • 32:52 Therapeutic Promise of Psychedelics • 34:43 Psychedelics + Spirituality • 37:37 Neuroscience of Psychedelics • 40:12 Epigenetics + Generational Trauma • 43:50 War on Drugs Revisited • 46:37 Future of Legalization • 49:55 MDMA for Couples • 51:29 Group Therapy with Psychedelics • 52:26 Psychedelic Science 2025 Preview See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matt Xavier is a full-time psychedelic guide, DJ, and mental health counselor whose remarkable career has spanned more than three decades at the intersection of music, healing, and expanded states of consciousness. In the early 1990s, Matt gained prominence as “Matthew Magic,” a pioneering force in New York City's underground electronic music scene. As cofounder of Tsunami Productions, he introduced Psychedelic Trance to the North American East Coast and later founded the influential techno label Railyard Recordings. Throughout his tenure, he held DJ residencies in both New York and Los Angeles, performing at renowned festivals and clubs around the world. Educated at Loyola Marymount University and credentialed in California, Matt has worked as a certified Gestalt therapist and co-occurring addiction counselor, providing evidence-based care at leading treatment centers across Los Angeles. In 2019, he received formal training in psychedelic-assisted therapy and launched Integrated Psychedelics—a private practice offering harm-reduction therapy, integration counseling, and immersive, music-enhanced psychedelic journeys. Through his work with Therapeutic DJing, Matt teaches others how to harness the powerful synergy between music and psilocybin-assisted therapy to support emotional release, healing, and deep personal transformation. Career News: Book release Early June 2025:  The Psychedelic DJ - A Practical Guide to Therapeutic Music Curation and Psilocybin-Assisted Therapy DJ Sets @ Psychedelic Science Conference June 2025: Shulgin 100 Year Birthday Celebration @ Psychedelic Science 2025 - Denver, feat. Oona Dahl & Matt Xavier AFTERGLOW: unofficial ambient-techno afterhours for Psychedelic Science 2025 - Denver, feat. Oona Dahl & Matt Xavier Matt's Links Mr. Bill's Links

GUEST:   https://www.wildwisebotanicals.com/   https://www.instagram.com/wildwisebotanicals/   MENTIONS:   https://momyco.org/   https://www.amazon.com/Missouris-Wild-Mushrooms-Maxine-Stone/dp/1887247742   https://namyco.org/  https://mycota.com/   https://www.fs.usda.gov/r09/marktwain   MUSHROOM HOUR:   https://welcometomushroomhour.com    https://instagram.com/welcome_to_mushroom_hour   https://tiktok.com/@welcome_to_mushroom_hour   Show Music courtesy of the one and only Chris Peck: https://peckthetowncrier.bandcamp.com/   TOPICS COVERED:   Growing up in Rural Ozarks   Crohns Disease   Wild Medicine    Homesteading and Homeschooling   The Ozarks as an Understudied Bioregion   Missouri Mycological Society   Maxine Stone   Certified Mushroom Identifiers   Developing Mushroom Certification Courses   Genetic Sequencing     Wildwise Botanicals  “Foraging Mushrooms of the Ozarks”    

From psychedelic breakthroughs to breaking the boundaries of compassion, Duncan Trussell and Raghu Markus offer unfiltered wisdom on the messy magic of waking up.Take the opportunity to support Ram Dass' Love Serve Remember Foundation and step into another dimension with a one-of-a-kind pair of custom Midnight Gospel sneakers. Hand-crafted by The Shoe Surgeon to replicate the iconic shoes worn by Clancy himself in the groundbreaking animated series by Duncan Trussell and Pendleton Ward. All proceeds benefit the Love Serve Remember Foundation and their work to preserve and continue the teachings of Neem Karoli Baba and Ram Dass. CLICK HERE to bid on the shoes and find more exciting one-of-a-kind collector's items at the LSRF Auction HERE.This time on Mindrolling, Duncan and Raghu connect over: The Good Friday psychedelic experiment New MDMA research with octopuses and insights into social neuroscienceBrain scans of Tibetan monks practicing loving-kindness (Metta) meditation‘Making the most' of the neuroplasticity that can occur during a psychedelic experience The most powerful issue we have to deal with: identity Transactional compassion versus offering genuine love and care to all Reversing our own neurosis and breaking through the self-created boundaries of compassionEmbracing spiritual discipline through the daily grind of practiceMoving through what the Buddhists call ‘the original heart of sadness' Maladaptive behaviors that we develop to mask the pain of humanity Alcohol as the west's faulty ‘ayahuasca' and initiation practice Self-compassion and allowing ourselves to be humanToday's episode is sponsored by Psychedelic Science 2025 & Reunion:Join the most important psychedelic gathering of the year......bridging science, spirit & society at Psychedelic Science 2025: THE INTEGRATION, hosted by the Multidisciplinary Association for Psychedelic Studies. Be part of the movement that will shape the next era of mental health, medicine, and consciousness.Featuring speakers like Paul Stamets, United States Representative Tim Ryan, Rick Doblin, founder of Internal Family Systems (IFS) Richard Schwartz, Pilar Guzman, CEO/Medical Director of the APA Marketa M. Wills, Raghu Markus, comedian Reggie Watts, musicians TYCHO & Jim James, and many more!Listeners get 15% off tickets to the 5-day event with our promo code LSRF15 at PsychedelicScience.orgMindrolling is brought to you by Reunion. Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code “BeHere250” when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.orgAbout Duncan Trussell:Duncan Trussell is a stand-up comedian, podcaster, and actor. His popular podcast, The Duncan Trussell Family Hour, has been downloaded over 25 million times and is known for its blend of humor, fringe ideas, eclectic guests, and great interviews. The DTFH is the foundation for Duncan's Netflix animated series, The Midnight Gospel, which he co-created with Pendleton Ward in 2020. To learn more about Duncan's work, visit his website at duncantrussell.com.“What do you do when you're passing strangers in the street and you love them completely? It's not bullshit. You feel about them the way you feel about someone you love, like your mother. What happens when the boundary of compassion breaks through and there is no longer this person deserves compassion, this person doesn't. It's like a dam broke." – Duncan TrussellSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this interview from 1977, Ram Dass shares his views on psychedelics and how they can provide a free slate to experience the innocence of consciousness once again. Join the most important psychedelic gathering of the year......bridging science, spirit & society at Psychedelic Science 2025: THE INTEGRATION, hosted by the Multidisciplinary Association for Psychedelic Studies. Be part of the movement that will shape the next era of mental health, medicine, and consciousness.Featuring speakers like Paul Stamets, United States Representative Tim Ryan, UCSF Neuroscience & Psychopharmacology Researcher Robin Carhartt-Harris, Rick Doblin, founder of Internal Family Systems (IFS) Richard Schwartz, Pilar Guzman, CEO/Medical Director of the American Psychiatric Association Marketa M. Wills - M.D., M.B.A., FAPA, Raghu Markus, comedian Reggie Watts, musicians TYCHO & Jim James, and many more!Listeners get 15% off tickets to the 5-day event with our promo code LSRF15 at PsychedelicScience.orgThis episode of Here and Now is from an interview with Ram Dass conducted by New Dimensions Radio in 1977, shortly after Ram Dass participated in a conference called “LSD – A Generation Later.” The interview begins with Ram Dass discussing the happenings at the conference and his interactions with other psychedelic luminaries, including Timothy Leary, Ralph Metzner, and Albert Hofmann. Ram Dass explores the culture surrounding LSD in 1977, and how he has no desire to legislate how other people live their lives. He shares his guru's instructions for using the “yogi medicine” and talks about whether or not it's important to have a guide for psychedelic experiences.Finally, Ram Dass cautions that “getting high and seeing” is only one part of the process of change, and there are inner processes necessary to bring about change in life. He discusses the cultural evolution brought about by psychedelics and the shifts in consciousness he sees taking place. The Ram Dass community gathers regularly to engage in meaningful discussions about the podcast. We invite you to join us and share your curiosities, insights, and wisdom. Sign up for the General Fellowship to receive event invitations directly in your inbox.Sponsors of this Episode:This show is sponsored by Magic Mind, a matcha-based energy shot infused with nootropics and adaptogens designed to crush procrastination, brain fog, & fatigue. Check out their new Maxx & Free energy shots and get 60% off your subscription with our code RAMDASS60 at magicmind.com/ramdassmfRam Dass Here & Now is also brought to you by BetterHelp. Give online therapy a try at betterhelp.com/ramdass and get on your way to being your best self.Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code BeHere250 when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.org“If you have a guide, you're calm, and you really want to explore your inner being, I still see LSD as an incredible vehicle for overriding your habitual response patterns, your habits of thought, and giving you a free slate to experience your innocence of consciousness once again.” – Ram DassSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes back Rick Doblin, Ph.D., Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), for a deeply personal and visionary conversation on the recent FDA rejection of MDMA-assisted therapy. Find full show notes and links here: https://thethirdwave.co/podcast/episode-306/?ref=278 Rick opens up about the painful setbacks, internal missteps, and his own process of recovery and renewed hope. He explains why this isn't the end—but a critical turning point for psychedelic medicine. Rick and Paul unpack the nuances of drug plus therapy, exploring why context, integration, and culture matter as much as pharmacology. They reflect on the future of MAPS, the psychedelic renaissance beyond FDA approval, and how business, politics, and spirituality intersect with healing. The episode also explores Rick's enduring belief in public benefit models, global collaboration, and the potential of a spiritualized humanity. Rick Doblin, Ph.D., is the Founder and President of MAPS. He received his doctorate in Public Policy from Harvard's Kennedy School of Government, and has spent nearly four decades advancing the safe and legal use of psychedelics and marijuana through science, education, and advocacy. Highlights: The cost of MAPS' quiet period Why MDMA therapy was rejected by FDA Pharma vs. therapy: What's best for patients? Drug-only treatments vs. integrated therapy Ibogaine's role in brain healing and PTSD MAPS' path forward: Phase 4 vs. Phase 3 What the Dutch got right about MDMA Spiritualized humanity and self-transcendence The global impact of MAPS' work Business, love, and psychedelic ethics Want to attend this year's Psychedelic Science 2025 Conference? For our community: Use code THIRDWAVE15 for 15% off registration. Learn more and register at psychedelicscience.org — See you there! Episode Links Psychedelic Science 2025 Conference MAPS Website Psychedelic Science on Instagram MAPS on Instagram Psychedelic Science on LinkedIn MAPS on LinkedIn Psychedelic Science on X Episode Sponsors: Golden Rule Mushrooms - Get a lifetime discount of 10% with code THIRDWAVE at checkout Psychedelic Coacing Isntitute's Intensive for Psychedelic Professionals in Costa Rica - a transformative retreat for personal and professional growth.

In this episode of Perspectives, we speak with Benjamin Breen and Jonathan Moreno on the history of psychedelic drugs in America. There is a resurgence of interest in psychedelics in the medical world as possible treatments for conditions such as depression, anxiety, and PTSD. This resurgence comes after a period during which psychedelic drugs were thought to be dangerous and have no medical value. An earlier perception was more optimistic. Figures such as Margaret Meade and Timothy Leary looked to drugs like peyote and LSD to allay fears, provide insights, broaden cultural perspectives and lead to chemical enlightenment. As mainstream institutions take yet another look, join us to examine the changing legal, medical and cultural perspectives on psychedelic drugs. Benjamin Breen is Associate Professor of history at the University of California, Santa Cruz. His second book is Tripping on Utopia: Margaret Meade, the Cold War and the Troubled Birth of Psychedelic Science. In addition to his academic publications, his writing has appeared in the The Washington Post, Paris Review Daily, The Atlantic, Slate, Aeon, The Pacific Standard, The Chronicle of Higher Education, The Public Domain Review, Nautilus, and Lapham's Quarterly. Jonathan Moreno is the David and Lyn Silfen University Professor Emeritus at University of Pennsylvania, where he works on bioethics, health policy, and the history and sociology of biology and medicine. He is the author of six books and numerous academic papers, and his work as also appeared in the New York Times, Wall Street Journal, Science, Nature, Slate, Politico, The Hill and Foreign Affairs. For more information on this and other topics, please see https://www.chstm.org/video/77474 Recorded on December 10, 2024.

Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD.  Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at www.psychedelicscience.org, and visit www.maps.org for information on MAPS Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode of The Zach Show, Adam Butler and Zach discuss DMT, the psychedelic molecule that Adam claims saved his life. From suicidal despair in the desert to conversations with God, demons, and dimensional beings, Adam recounts his transformation through DMT with brutal honesty and poetic grit. We unpack the “Miracle Molecule” from every angle: the effects of endogenous DMT, why it shows up at birth and death, its role in altered states, and what happens when you smoke, drink, or breathe your way into it. Adam shares his thoughts on DMT as a tool for shadow work, transcendental sex, artistic creativity, and spiritual rebirth. We also examine the fine line between mysticism and madness, and why he believes DMT is not just a drug, but a key to consciousness itself. Whether you're a seasoned psychonaut or a curious skeptic, this conversation will challenge your assumptions about reality, identity, and the nature of the soul. Guest Bio: Adam Butler is a psychedelic philosopher and passionate DMT psychonaut focusing on mental health, neuroplasticity, self-exploration, and the extreme limits of human potential and ability. He is the author of 'Butler's DMT Field Guide: A Brief History, Step-by-Step Recipes, and Personal Experiences From a DMT Saturated Consciousness' SUPPORT THE ZACH SHOW BY SUBSCRIBING TO THE ZACH SHOW 2.0 (BONUS EPISODES & EXCLUSIVE CONTENT): https://auxoro.supercast.com/ ADAM BUTLER LINKS:DMT Field Guide (Amazon): https://bit.ly/4jUQ33uInstagram: https://www.instagram.com/booksbyadambutler/YouTube: https://www.youtube.com/@ButlersDMTFieldGuide THE ZACH SHOW LINKS: Instagram: https://www.instagram.com/auxoroYouTube: https://bit.ly/3CLjEqFNewsletter: https://therealzachwrites.substack.com/TikTok: https://www.tiktok.com/@auxoropod To support the show, please leave a review on Spotify and Apple Podcasts. This nudges the algorithm to show The Zach Show to more new listeners and is the best way to help the show grow. Thank you for your support:  Review us on Apple Podcasts: https://bit.ly/458nbhaReview us on Spotify: https://bit.ly/43ZLrAt 

Zach Leary returns to Mindrolling to discuss his upcoming book on navigating the psychedelic boom of the 21st century. Preorder your copy of Zach's book, Your Extraordinary Mind: Psychedelics in the 21st Century and How to Use Them, HERE.Mindrolling is brought to you by Reunion. Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code “BeHere250” when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.orgThis week on Mindrolling, Raghu and Zach chat about:What propelled Zach to write his new book The explosion of psychedelic use in the 21st century Zach's personal history as the son of Timothy Leary and a close friend of Ram DassLaura Huxley's book on her father Aldous Huxley, This Timeless MomentThe film, Dying to Know, about Tim Leary and Ram DassThe origin story of LSD in the book Tripped by Norman OhlerMAPS work in redefining the modern age of psychedelics Pros and Cons of the medical movement in psychedelic research The benefits of practice coincided with psychedelics for inner expansionThe necessity of integration after a psychedelic experience Psychedelic research into neuroplasticity and transforming trauma Check out this MAPS page, where you can see a video of Ram Dass and Laura Huxley reading This Timeless Moment togetherAbout Zach Leary: Zach is a speaker, writer, Dharmic realizer, and psychedelic advocate. He is also a journey facilitator at Evolution Retreats and Heroic Path to Light. Zach hosts the MAPS (Multidisciplinary Association for Psychedelic Studies) Podcast where he explores an incredible treasure trove of audio archives sourced from the amazing talks, presentations, and panels that have taken place at past Psychedelic Science conferences and other unique events.Keep up with Zach on Instagram “I see far more success in the psychedelic sphere with people that have something to augment the experience with. If you go back to your desk on a Monday morning and are just unaware of these transformations and not making any effort to tap in, it will fade. I think it's an essential ingredient that you need to make it successful.” – Zach LearySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The breakthroughs we're seeing in psychedelic medicine today started with non-profit organizations taking risks that others wouldn't.Three organizations leading the charge are Multidisciplinary Association for Psychedelic Studies (MAPS), OPEN Foundation and Champalimaud Foundation.Psychedelic research faces unique hurdles, such as Schedule I drug classification, complex regulatory requirements, and historical stigma. Traditional funding sources (pharma, government and academia) often avoid these high-risk, long-term investments, which is where non-profits can make big strides. They tend to be mission-driven, patient-focused, and have a long-term commitment to research.Check out my latest Nina's Note to learn how these organizations push psychedelic research forward and act as bridge-builders between science and public understanding.

Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of the Journal of Clinical Psychopharmacology (JCP), leads a conversation about the guest editorial “Ethics in Psychedelic Science: Promises and Responsibilities” with its author, Dominic Sisti, PhD, a medical ethicist from the Perelman School of Medicine at the University of Pennsylvania, and a JCP podcast panel of Editor-in-Chief Dr. Anthony Rothschild and Associate Editor Dr. Richard Balon. Dr. Sisti provides an overview of recent regulatory actions in this area and summarizes the history of “utopian hype” in the field. The editorial and the podcast discussion detail what elements are required to build a solid ethics infrastructure for psychedelics research and clinical delivery that is free of hype and bias. Sisti advises moving ahead with caution, while noting that “the range of potentially treatable conditions is wide—including PTSD, major depression, anxiety disorder, obsessive compulsive disorder, anorexia nervosa, and substance use disorders.” The guest editorial is published in the January-February 2025 issue of JCP.

Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of the Journal of Clinical Psychopharmacology (JCP), leads a conversation about the guest editorial “Ethics in Psychedelic Science: Promises and Responsibilities” with its author, Dominic Sisti, PhD, a medical ethicist from the Perelman School of Medicine at the University of Pennsylvania, and a JCP podcast panel of Editor-in-Chief Dr. Anthony Rothschild and Associate Editor Dr. Richard Balon. Dr. Sisti provides an overview of recent regulatory actions in this area and summarizes the history of “utopian hype” in the field. The editorial and the podcast discussion detail what elements are required to build a solid ethics infrastructure for psychedelics research and clinical delivery that is free of hype and bias. Sisti advises moving ahead with caution, while noting that “the range of potentially treatable conditions is wide—including PTSD, major depression, anxiety disorder, obsessive compulsive disorder, anorexia nervosa, and substance use disorders.” The guest editorial is published in the January-February 2025 issue of JCP.

Welcome back to The Trip Report Podcast, a production of Beckley Waves.Today, I am speaking with Hailey Gilmore, the former Medical Science Liason at MAPS PBC, Lykos Therapeutics, and founder of Luminous Research ConsultingHailey joined MAPS in 2020, where she spearheaded their investigator-initiated trials (IIT) program, overseeing how MDMA-assisted therapy could address diverse clinical indications. Her role involved navigating complex regulatory landscapes, establishing protocols, and engaging with researchers worldwide.Today, as the founder of Luminous Research she leverages her expertise to guide organizations in bringing psychedelics and other innovative therapies to market.Hailey is a public health scientist with a master's degree in epidemiology and biostatistics from UC Berkeley. She has spent over 15 years in clinical trial management, initially in the HIV prevention field, where she contributed to groundbreaking studies such as the efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV transmission.This conversation is a masterclass in understanding psychedelic therapy development's nuanced challenges and opportunities.Here's what we cover:* The Landscape of Psychedelic Therapy: Hailey breaks down the logistical hurdles of bringing MDMA-assisted therapy to market, from FDA approvals to state-by-state legislative processes and the complex interplay of insurance, healthcare institutions, and drug rescheduling.* Insights from HIV Research: Drawing parallels with PrEP's rollout, Hailey provides a framework for how psychedelics might navigate similar adoption barriers, including clinician training, insurance buy-in, and the balancing act between small, agile clinics and large academic centers.* The Role of Smaller Clinics vs. Academic Institutions: She reflects on how smaller clinics might be better positioned to implement MDMA-assisted therapy quickly, given their flexibility, while larger institutions struggle to turn their metaphorical cruise ships.* Systemic Challenges in the Psychedelic Field: From the intricacies of DEA licensing to the limitations of current research funding, Hailey outlines the systemic barriers that continue to slow progress in this field.* Optimism Amid Complexity: Despite the delays in MDMA-assisted therapy's approval, Hailey believes that public-private partnerships and innovative trial designs could unlock new opportunities for psychedelic research and implementation.Finally, we explore the potential impact of Robert F. Kennedy Jr.'s potential appointment as Secretary of Health and Human Services in the Trump administration. Could this mark a turning point for federal policy on psychedelics? Hailey weighs the possibilities and shares her vision for how public health could guide this evolving conversation.And now, I bring you my conversation with Hailey Gilmore.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney* Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

In this episode, Joe interviews Rick Doblin, Ph.D.: founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), and former board member at Lykos Therapeutics, MAPS' public benefit subsidiary. Doblin tells his side of the story: that the FDA's concerns with double blinding not working had been fully addressed ahead of time, that they had negotiated agreements that were no longer agreed to when new FDA employees came on board, that there was a lot of confusion from going back and forth with the FDA on how Phase 3 studies should be designed, and more. He believes that Lykos made a massive mistake in assuming that provable science was more important than public opinion, and that ignoring critics who were saying whatever they wanted caused them to lose control of the narrative – which clearly influenced the advisory committee. While Lykos figures out their next steps with the FDA, MAPS is focusing their attention on what they feel is most important in light of this ruling: better public education and drug policy. He talks about: How there's a bias at the FDA to be harsh: Does automatically saying no just make it look like you're being rigorous? The work of the Dutch government in researching MDMA, and Lykos' odd decision to not highlight any of it Massachusetts' Legalization and Regulation of Psychedelic Substances initiative, and the huge opportunity for progress at the local level Why federal agents at Burning Man work so hard to give tickets to attendees for smoking cannabis Why sharing stories of your positive experiences with psychedelics is so important and more!  MAPS has announced that 2025's Psychedelic Science conference will be in Denver, June 16-20, and will have experiential opportunities before and after.  For links, head to the show notes page. 

We speak with historian Ben Breen (UC Santa Cruz) about the writing of his recent book, Tripping on Utopia: Margaret Mead, the Cold War, and the Troubled Birth of Psychedelic Science, We discuss how to think about chapter organization; writing about individuals' lives without writing biography; discovering our main characters through the writing process; books that have served as models for writing; the wonderfulness of Terry Gross; not getting caught up in the apparatus of writing tools; and why it's most important to just get the ideas down. Don't forget to rate and review our show and follow us on all social media platforms here: https://linktr.ee/writingitpodcast Contact us with questions, possible future topics/guests, or comments here: https://writingit.fireside.fm/contact

Delve into the fascinating world of psychedelics with Dr. Harriet De Wit, a renowned expert in psychiatry and behavioral neuroscience. Discover what truly happens in the brain during psychedelic experiences, from the science behind microdosing to the potential of psychedelics as treatments for mood disorders and even PTSD. Dr. De Wit provides insights into the effects of MDMA and LSD, the history of these substances, and how societal perceptions are shifting. Plus, get a sneak peek into Reese's 100th Book Club pick, "The Comfort of Crows" by Margaret Renkl, and how it beautifully intertwines memoir and nature writing. See omnystudio.com/listener for privacy information.

In this episode, Joe interviews Devon Phillips: community & partnerships officer for the Multidisciplinary Association for Psychedelic Studies (MAPS). Phillips works on strategies to tackle the questions: How do we responsibly mainstream psychedelics? And how do we get culture engaged? He's focusing on being the bridge to psychedelics outside of research, facilitating workshops and psychedelic coming-out stories at music festivals and conferences. He talks about harm reduction and drug checking at festivals, the concept of training big names to become trustworthy resources, the differences found in a hop hop crowd compared to EDM, and the power in using psychedelics for pleasure and celebration – not just healing and growth.  He also discusses:  MAPS' involvement with the NFL for their 'My Cause, My Cleats' campaign, and how the San Francisco 49ers' Jon Feliciano is bringing awareness to psychedelic healing Details about MAPS' first responders training, fiscal sponsorship program, international therapist education program, and upcoming membership program (launching in June) The success of MAPS' Psychedelic Science and his hopes for the 2024 edition, taking place June 16 - 20 at the Denver Convention Center Dr. Carl Hart, drug exceptionalism, and the importance of creating safe containers and inclusive drug policy  and more! For links and more, head to the show notes page.

Psychedelic drugs have been illegal for 50 years, but they're trickling back into the mainstream because they show promise in helping treat post-traumatic stress disorder and other mental health challenges. We begin the hour with reporter Jonathan A. Davis visiting Psychedelic Science 2023, the largest-ever conference on psychedelic drugs. It's put on by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to legalizing MDMA (also known as ecstasy or molly) and other psychedelic drugs. Research shows that MDMA-assisted therapy can help treat depression and PTSD, and it's moving toward approval by the U.S. Food and Drug Administration. Psychedelics were studied in the 1950s and '60s as mental health treatments, but the war on drugs put a stop to research. Now, these drugs are gaining bipartisan support from politicians looking for solutions to the mental health crisis among veterans.  Then Reveal's Michael I Schiller visits a group of veterans who are not waiting for psychedelic-assisted therapy to be approved by the federal government. They've joined a church founded by an Iraq War veteran who uses psychedelics as religious sacraments. Schiller accompanies them on a retreat in rural Texas, where they share the depths of their post-traumatic stress and the relief they've felt after psychedelic treatments. He also explores the risks involved in taking these drugs.  We close with an intimate audio diary from a woman in Oakland, California, who's going through therapy with the one psychedelic drug that can be legally prescribed currently in the U.S.: ketamine. Ketamine started out as an anesthetic, but researchers found it can help with treatment-resistant depression when used in tandem with talk therapy. Ketamine can be dangerous if abused, but it also has helped people find relief from mental health issues. This story was produced by Davis.  This is an update of an episode that originally aired in October 2023. Support Reveal's journalism at Revealnews.org/donatenow Subscribe to our weekly newsletter to get the scoop on new episodes at Revealnews.org/newsletter Connect with us on Twitter, Facebook and Instagram Check out independent producer Jonathan A. Davis's work here

If you're listening to this podcast, chances are you've heard stories about the CIA's experiments with drugs, particularly LSD, during the infamous MKUltra program. But you may not know that the characters involved in that dubious effort connect to one of the 20th Century's most famous and revered scientists, the anthropologist Margaret Mead. Shane Harris talked with historian Benjamin Breen about this new book, Tripping on Utopia, which tells the story of how Mead and her close circle launched a movement to expand human consciousness, decades before the counterculture of the 1960s popularized, and ultimately stigmatized, psychedelic drugs. Mead and Gregory Bateson--her collaborator and one-time husband--are at the center of a story that includes the WWII-era Office of Strategic Services, a shady cast of CIA agents and operatives, Beat poets, and the pioneers of the Information Age. Psychedelics are having a renaissance, with federal regulators poised to legalize their use - Breen's book is an engrossing history that explores the roots of that movement and how it influenced and collided with the U.S. national security establishment. Books, movies, and other points of interest discussed in this conversation include: Tripping on Utopia: Margaret Mead, the Cold War, and the Troubled Birth of Psychedelic Science by Benjamin Breen Tripped: Nazi Germany, the CIA, and the Dawn of the Psychedelic Age by Norman Ohler MKUltra The intelligence community's research on “truth drugs” The Manchurian Candidate The Good Shepherd Poisoner in Chief: Sidney Gottlieb and the CIA Search for Mind Control by Stephen Kinzer The Men Who Stare at Goats by Jon Ronson Ghost Hunters: William James and the Search for Scientific Proof of Life After Death by Deborah Blum “Operation Delirium” by Raffi Khatchadourian in The New Yorker Also check out: Ben's website Ben's Substack Ben on Twitter Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.

The twentieth century was something, wasn't it? Margaret Mead, as well as her onetime-husband Gregory Bateson, managed to play roles in several of its key developments: social anthropology and its impact on sex & gender mores, psychedelic drugs and their potential use for therapeutic purposes, and the origin of cybernetics, to name a few. Benjamin Breen discusses this impactful trajectory in his new book, Tripping on Utopia: Margaret Mead, the Cold War, and the Troubled Birth of Psychedelic Science. We talk about Mead and Bateson, the early development of psychedelic drugs, and how the possibility of a realistic utopia didn't always seem so far away.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2024/02/26/267-benjamin-breen-on-margaret-mead-psychedelics-and-utopia/Support Mindscape on Patreon.Benjamin Breen received his Ph.D. in history from the University of Texas at Austin. He is currently an associate professor of history at the University of California, Santa Cruz. Among his awards are the National Endowment for the Humanities Award for Faculty and the William H. Welch Medal of the American Association for the History of Medicine. He writes on Substack at Res Obscura.Web siteUCSC web pageWikipediaAmazon author pageSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Emma Stone is nominated for an Oscar for her starring role in Poor Things. She spoke with Terry Gross about the film and her relationship to her anxiety. David Bianculli reviews Ryan Murphy's FX anthology series Feud: Capote vs. The Swans. Also, Benjamin Breen talks about his book, Tripping on Utopia: Margaret Mead, the Cold War, and the Troubled Birth of Psychedelic Science. It's about the pioneering work anthropologists Margaret Mead and Gregory Bateson did on the use of psychedelics as a way to expand consciousness, and how that later connected to government research on the use of psychedelics as a weapon.

You may have heard about the pioneering research of anthropologist Margaret Mead, but do you know about her work with psychedelics? Mead and her husband, Gregory Bateson, thought psychedelics might reshape humanity by expanding consciousness. We'll speak with author Benjamin Breen about that research and how it led to the CIA's secret experiments in the '50s and '60s, using psychedelics in interrogation. He also shares with us details about a NASA-funded experiment to try to get dolphins to talk by giving them LSD. His book is Tripping on Utopia.Also, John Powers reviews the Apple TV+ series Criminal Record.

Psychedelic drugs have been illegal for 50 years, but they're trickling back into the mainstream because they show promise in helping treat post-traumatic stress disorder and other mental health challenges. We begin the hour with reporter Jonathan A. Davis visiting Psychedelic Science 2023, the largest-ever conference on psychedelic drugs. It's put on by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to legalizing MDMA (also known as ecstasy or molly) and other psychedelic drugs. Research shows that MDMA-assisted therapy can help treat depression and PTSD, and it's moving toward approval by the U.S. Food and Drug Administration. Psychedelics were studied in the 1950s and '60s as mental health treatments, but the war on drugs put a stop to research. Now, these drugs are gaining bipartisan support from politicians looking for solutions to the mental health crisis among veterans.  Then Reveal's Michael I Schiller visits a group of veterans who are not waiting for psychedelic-assisted therapy to be approved by the federal government. They've joined a church founded by an Iraq War veteran who uses psychedelics as religious sacraments. Schiller accompanies them on a retreat in rural Texas, where they share the depths of their post-traumatic stress and the relief they've felt after psychedelic treatments. He also explores the risks involved in taking these drugs.  We close with an intimate audio diary from a woman in Oakland, California, who's going through therapy with the one psychedelic drug that can be legally prescribed currently in the U.S.: ketamine. Ketamine started out as an anesthetic, but researchers found it can help with treatment-resistant depression when used in tandem with talk therapy. Ketamine can be dangerous if abused, but it also has helped people find relief from mental health issues. This story was produced by Davis. Support Reveal's journalism at Revealnews.org/donatenow Subscribe to our weekly newsletter to get the scoop on new episodes at Revealnews.org/newsletter Connect with us on Twitter, Facebook and Instagram Check out independent producer Jonathan A. Davis's work here